Maximizing the cGMP System in Preclinical Left Ventricular and Renal Dysfunction

最大限度地发挥 cGMP 系统在临床前左心室和肾功能障碍中的作用

• 批准号: 8203720
• 负责人: HORNG H CHEN
• 金额: $ 49.45万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-08-15 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8203720
• 关键词: Agonist; Biology; Brain natriuretic peptide; Cardiac; Cardiovascular system; Chronic; Cyclic GMP; Development; Event; FDA approved; Functional disorder; Funding; Goals; Heart; Heart failure; Human; Kidney; Left; Left Ventricular Dysfunction; Medicine; Methods; Morbidity - disease rate; Natriuretic Peptides; Pathway interactions; Patients; Peptides; Pharmaceutical Preparations; Principal Investigator; Public Health; Regulation; Renal function; Risk; Structure; Symptoms; System; Ventricular; atrial natriuretic factor receptor A; base; improved; mortality; novel therapeutics; pre-clinical; professor; programs; tadalafil; therapy development

Program Oirector/Principal Investigator (Last, First, Middle): Bumett, John, C, Jr. PROJECT 3 Title: Maximizing the cGMP System in Preclinical Left Ventricular and Renal Dysfunction Project Description: Heart failure is a growing public health problem with high mortality and morbidity. The concept of preclinical heart failure is based on the fact that abnormal heart structure/function can be detected by complementary methods before the development of symptoms. Patients with those abnormalities may progress to symptomatic heart failure and are at increased risk of adverse cardiac events. This human translational project aims to develop novel therapeutics by maximizing the cGMP system using two FDA approved medications, Nesiritide and Tadalafil. to improve renal funcfion pafients with preclinical heart failure. Our goals are to further our understanding the cGMP pathway in the mechanism of renal dysfunction in preclinical heart failure and to develop therapies to improve the renal function with the hope of delaying the progression of preclinical heart failure to symptomatic heart failure. Project Leader: Horng H. Chen. MD; Associate Professor of Medicine Other

项目负责人/首席调查员(最后、第一、中间)：Bumett，John，C，Jr. 项目3 标题：临床前左心和肾的cGMP系统最大化 功能障碍 项目简介：心力衰竭是一个日益严重的公共健康问题，死亡率和发病率都很高。这个 临床前心力衰竭的概念是基于可以检测到心脏结构/功能异常的事实 在出现症状前采用补充方法治疗。有这些异常的患者可能 进展为症状性心力衰竭，发生不良心脏事件的风险增加。这个人类 翻译项目旨在通过使用两个FDA最大化cGMP系统来开发新的治疗药物 批准的药物奈西立德和他达拉非。目的：改善临床前心力衰竭患者的肾功能。 我们的目标是进一步了解cGMP通路在肾功能不全发病机制中的作用。 临床前心力衰竭和开发改善肾功能的治疗方法，希望延缓 临床前心力衰竭进展为症状性心力衰竭。 项目负责人：陈宏华。医学副教授 其他